The present invention describes a process for the preparation of an antigen composition, which antigen composition can be used to prepare a ready-to-use vaccine for swine, for preventing or reducing infection by M. hyo or PCV2 and associated signs of disease. The process is characterised in that it comprises a step of admixing a PCV2 antigen to a pre-formed antigen/adjuvant complex of an M. hyo antigen adsorbed to an Aluminium-hydroxide adjuvant. This way a PCV2/M. hyo combination vaccine can be prepared that is highly effective already after a single administration, against infection and disease by M. hyo and PCV2 either when in single or in combined infections. Also the vaccine has very good safety upon administration, is ready-to-use, and is economically feasible.

The present invention is directed to novel polynucleotides, polypeptides, and polyproteins of Mycoplasma surface proteins, all of which are useful in detecting infection and for the preparation of vaccines for treating and preventing diseases in swine and other animals. Vaccines provided according to the practice of the invention are effective against Mycoplasma infections. Detection and therapeutic polyclonal and monoclonal antibodies are also a feature of the present invention. Assays, kits, systems, and nanoparticle encapsulated compositions related to the polynucleotides, polypeptides, polyproteins, antibodies or fragments, derivatives, and variants thereof are also disclosed.

An improved vaccine for immunization of waterfowl such as ducks and geese comprises an inactivated strain of a Mycoplasma infecting waterfowl, such as Mycoplasma sp. strain 1220; the vaccine can include an excipient and an adjuvant. Methods for immunization of waterfowl with the vaccine are also described.

Compositions for use in diagnostic screens for Mycoplasma haemofelis are provided. In one embodiment an immunogenic peptide selected from SEQ ID NO: 1 to SEQ ID NO: 60, or a fragment thereof, is immobilized on a solid support and is used to detect the presence of Mycoplasma haemofelis antibodies in a patient bodily fluid. In accordance with one embodiment a method for detecting a Mycoplasma haemofelis infection in a feline species, is provided.

The present invention relates to non-mercurial preservatives, including antimicrobial polyamide polymers and octenidine, and to methods of use thereof to produce preservative-containing multi-dose formulations. The preservative-containing multi-dose formulations exhibit resistance to one or more contaminating microorganisms, and have advantageous properties with respect to long term stability of biological and small molecule active ingredients.

The present disclosure relates to a composition for preventing and treating Mycoplasma synoviae infection, the composition comprising Tuf, NOX, MS53-0285 or a combination thereof as active ingredients. The composition of the present disclosure is effective in alleviating symptoms caused by Mycoplasma synoviae infection and can be used as an effective tool in preventing or treating poultry diseases.

A vaccine composition for birds comprising as an active ingredient a structure containing O-antigen derived from Gram-negative bacteria, provided that said structure does not contain a whole cell, and a process for preparing the same are provided. By using a structure containing O-antigen (e.g. lipopolysaccharide) derived from Gram-negative bacteria as an active ingredient in accordance with the present invention, alleviation of inoculation reaction and reduction in an amount of injection are attained as compared to the conventional whole-cells vaccine to thereby allow for the increase in the number of other antigens to be mixed therewith.

The present disclosure provides an adjuvant composition containing 0.2%-15% w/v carbomer, 0.1%-0.5% w/v lecithin, and 0.03%-0.2% w/v ginsenoside. The adjuvant composition of the present disclosure cannot only ensure the long-term clarification and/or stability of the vaccine, but also can effectively stimulate the inactivated antigens and subunit antigens therein to produce high-titer antibodies for immune protection. The inactivated vaccines or subunit vaccines prepared by the adjuvant composition of the present disclosure can be used as a diluent for freeze-dried live virus antigens and has no toxic effect on the live virus antigens.

The invention provides in part methods of treating cancers of a specific organ or tissue by administering a composition that is antigenically specific for one or more microbes that are pathogenic in the specific organ or tissue in which the cancer is situated.

The present invention relates to a complex of polyproteins containing immunogenic regions derived from the P36, P46, HSP, NrdF, P97, MHP271 e P216 antigens of M. hyopneumoniae, which regions are fused with segments of the Rrp4. Rrp41 and Rrp42 carrier proteins of P. abyssi, forming a single complex. The present invention further provide the following objects: (i) a gene coding the polyprotein complex, which complex is based on the exosome of P. abyssi and carries copies of vaccine antigens of M. hyopneumoniae; (ii) an antigenic composition comprising the polyprotein complex of the invention, optionally one or more auxiliary agents and/or additives and a pharmacologically acceptable excipient; (iii) a method for producing said polyprotein complex; and (iv) uses of said complex and composition in the treatment and prevention of disease caused by M. hyopneumoniae infection.